Format

Send to

Choose Destination
J Cyst Fibros. 2014 Dec;13(6):716-22. doi: 10.1016/j.jcf.2014.02.007. Epub 2014 Mar 11.

Improvement of digestive health and reduction in proteobacterial populations in the gut microbiota of cystic fibrosis patients using a Lactobacillus reuteri probiotic preparation: a double blind prospective study.

Author information

1
Department of Microbiology, Hospital Universitario Ramón y Cajal, Spain; Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain; Spanish Network for the Research in Infectious Diseases (REIPI), Instituto de Salud Carlos III, Spain. Electronic address: rosacampo@yahoo.com.
2
Cystic Fibrosis Unit, Hospital Universitario Ramón y Cajal, Madrid, Spain.
3
Department of Pediatrics, Virgen de las Nieves and San Cecilio University Hospitals, Granada, Spain.
4
Department of Gastroenterology, Hospital Parc Tauli, Sabadell, Spain.
5
Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain; Cystic Fibrosis Unit, Hospital Universitario Ramón y Cajal, Madrid, Spain.
6
Deparment of Biochemistry, Hospital Universitario Ramón y Cajal, Madrid, Spain.
7
Department of Immunology, Hospital Universitario Ramón y Cajal, Madrid, Spain.
8
Department of Microbiology, Hospital Universitario Ramón y Cajal, Spain; Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain; Spanish Network for the Research in Infectious Diseases (REIPI), Instituto de Salud Carlos III, Spain.
9
Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain; Clinical Biostatistics Unit, Hospital Universitario Ramón y Cajal, Madrid, Spain; Center for Network Research in Epidemiology and Public Health (CIBERESP), Spain.
10
Department of Microbiology, Hospital Universitario Ramón y Cajal, Spain; Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain; Center for Network Research in Epidemiology and Public Health (CIBERESP), Spain.

Abstract

BACKGROUND:

Although scientific knowledge about the benefits of probiotic use in cystis fibrosis (CF) is scarce, their expectative is promising. The aim of this work was to analyze the effect of a Lactobacillus reuteri probiotic preparation versus placebo in CF patients.

METHODS:

A prospective, double blind, crossover and with placebo study was carried out in 30 CF patients from two Spanish hospitals. Patients were randomized in Group A (6 months of probiotic followed by 6 months of placebo) and Group B (6 months of placebo followed by 6 months of probiotic). GIQLI (gastrointestinal) and SF-12 (general) health tests were performed after probiotic and placebo intakes. Fat absorption coefficient, calprotectin, and inflammatory interleukin quantification were determined in fecal samples. Total fecal DNA was obtained and metagenomic 454-pyrosequencing was applied to analyze the microbiome composition. STATA v12 MP software was used for statistical analyses.

RESULTS:

Statistically significant improvement in the gastrointestinal health and decrease of the calprotectin levels were demonstrated in patients after probiotic exposure, in comparison with placebo. All CF subjects reported good tolerance to L. reuteri without secondary effects. Metagenomic analysis showed an important dysbiosis in CF gut microbiota associated with a high concentration of Proteobacteria. Probiotic intake was followed by a reduction in the total bacterial density, mostly due to a considerable reduction in the γ-Proteobacteria phylum; and an important increase of the microbial diversity with a higher representation of Firmicutes.

CONCLUSIONS:

Probiotics might ameliorate the dysbiosis of CF gut microbiota, characterized by a high density of Proteobacterial organisms. L. reuteri significantly decrease intestinal inflammation and increase digestive comfort.

KEYWORDS:

Digestive health; Intestinal microbiota; Lactobacillus reuteri; Probiotics

PMID:
24636808
DOI:
10.1016/j.jcf.2014.02.007
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center